PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Jaundice, Obstructive”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 487 records · Page 27Linked to original sources
PubMed1981

[Percutaneous transhepatic biliary drainage in obstructive jaundice].

PTC was performed in 86 patients with obstructive jaundice, between February/80--March/81 diagnosing 20 cases of the hepatic hilium carcinoma, 14 of pancreatic carcinoma, and 2 multiplex abscess of the liver. PTC-D was successfully attempted on 16 patients, catheterizing the intrahepatic biliary tree in 15 and maintaining a good biliary flow in 10 of them. The catheter was on the correct position into the biliary tree in 6 patients, and the drainage continued for 7-20 days. General improvement was obtained in 83.33%, itching decreased in 40% and disappeared in 60%, cholestasis was reduced in 100% and sepsis in 75%. Complications of the technique were: pain during the introduction of the guide wire (18.75%) and transitory hemobilia (31.21%). PTC-D seems to be a procedure with a precisely indication in every transitory obstructive jaundice, in order to put the patient in better conditions to a definitive therapy: 1) Surgery 2) Prosthesis 3) External-internal biliary drainage.

Aged↗
PubMed2003

Percutaneous biliary metal wall stenting in malignant obstructive jaundice.

BACKGROUND: Most patients with advanced stage malignant obstructive jaundice will be suitable for palliation only. Metallic stents are safe, effective and minimally invasive. DESIGN: A review of case notes of patients who had Wallstents inserted percutaneously from January 1996 to December 2000. RESULTS: Eighty-nine patients with a median age of 72 years underwent percutaneous insertion of biliary metal stents. The diagnoses were cholangiocarcinoma (41.5%), pancreatic carcinoma (40.5%), nodal metastases at the porta hepatis (14.6%) and gall bladder cancer (3.4%). Ninety-six per cent of patients improved their hyperbilirubinaemia to normal levels by 1 month. The median post-procedure hospital stay was 16 days. Early overall complications (within 30 days of stenting) occurred in 30% of patients (70% of these were disease related). The 30 day mortality rate was 20% (n = 18). Fifty (70%) patients were readmitted to hospital, most commonly because of carcinomatosis (16) or stent obstruction (12). The symptom-free period ranged from 2 weeks to 13 months. Median survival for all patients was 3.5 months. Survival correlated inversely with serum bilirubin at presentation (r = -0.34, P = 0.001), but not with other liver function tests. DISCUSSION: Metal wall stenting for malignant obstructive jaundice provides good palliation with low, procedure-related morbidity and mortality, but poor overall survival from disease-related morbidity. Survival significantly correlates with pre-stenting serum bilirubin levels. There is a need to identify the subgroup of patients in whom stenting has no beneficial effect.

Aged↗